New Terocin

Methyl Salicylate, Capsaicin, And Menthol


Lake Erie Medical Dba Quality Care Products Llc
Human Otc Drug
NDC 35356-963
New Terocin also known as Methyl Salicylate, Capsaicin, And Menthol is a human otc drug labeled by 'Lake Erie Medical Dba Quality Care Products Llc'. National Drug Code (NDC) number for New Terocin is 35356-963. This drug is available in dosage form of Lotion. The names of the active, medicinal ingredients in New Terocin drug includes Capsaicin - .025 g/100mL Menthol - 10 g/100mL Methyl Salicylate - 25 g/100mL . The currest status of New Terocin drug is Active.

Drug Information:

Drug NDC: 35356-963
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: New Terocin
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Methyl Salicylate, Capsaicin, And Menthol
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Lake Erie Medical Dba Quality Care Products Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Lotion
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CAPSAICIN - .025 g/100mL
MENTHOL - 10 g/100mL
METHYL SALICYLATE - 25 g/100mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 13 Mar, 2013
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Lake Erie Medical DBA Quality Care Products LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1372464
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
UNII:S07O44R1ZM
L7T10EIP3A
LAV5U5022Y
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
35356-963-11120 mL in 1 BOTTLE (35356-963-11)13 Mar, 2013N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose topical analgesic

Product Elements:

New terocin methyl salicylate, capsaicin, and menthol methyl salicylate salicylic acid capsaicin capsaicin menthol menthol water propylene glycol cetyl alcohol stearic acid glyceryl monostearate peg-100 stearate dimethyl sulfone lidocaine lavender oil aloe vera leaf borage oil indian frankincense xanthan gum trolamine methylparaben propylparaben dmdm hydantoin iodopropynyl butylcarbamate

Indications and Usage:

Uses temporarily relieves mild aches and pains of muscles or joints.

Warnings:

Warnings only for external use. do not use: on open wounds, cuts, damaged or infected skin as well as in the eyes, mouth, genitals, or any other mucous membranes. consult your physician: if pain is persistent or worsens or if using any other topical pain products. call poison control if swallowed. if contact with the eyes occurs, rinse eyes thoroughly with cold water.

Dosage and Administration:

Directions wash and dry affected area. shake bottle well before each use and gently rub over area of pain. use is not recommended more than four times a day. wash hands immediately afterwards to avoid contact with eyes.

Package Label Principal Display Panel:

Image description


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.